Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials

• DOI: 10.1007/s00198-024-07049-w
• Publication Date: 2024-04-04T04:07:37Z
• Authors: J. Lane; B. Langdahl; M. Stone; A. Kurth; M. Oates; J. Timoshanko; Z. Wang; C. Libanati; F. Cosman
• Keywords: Post-hoc analysis; Denosumab

Post hoc analysis of FRAME and ARCH revealed that on-study nonvertebral vertebral fractures by Month 12 were less common in women initially treated with romosozumab versus placebo or alendronate. Recurrent fracture risk was also lower romosozumab‑treated patients, there no fracture‑related complications. Results support continuing treatment post‑fracture.